Characterizing the Detection Threshold for Optical Imaging in Surgical Oncology

Overview

Journal J Surg Oncol

Specialties General Surgery
Oncology

Date 2017 Jun 20

PMID 28628728

Citations 6

Authors

Andrew C Prince

Aditi Jani

Melissa Korb

Kiranya E Tipirneni

Benjamin B Kasten

Eben L Rosenthal

Jason M Warram

Affiliations

Soon will be listed here.

Abstract

Background And Objectives: Optical imaging to guide cancer resections is rapidly transitioning into the operating room. However, the sensitivity of this technique to detect subclinical disease is yet characterized. The purpose of this study was to determine the minimum range of cancer cells that can be detected by antibody-based fluorescence imaging.

Methods: 2LMP (breast), COLO-205 (colon), MiaPaca-2 (pancreas), and SCC-1 (head and neck) cells incubated in vitro with cetuximab-IRDye800CW (dose range 8.6-86 nM) were implanted subcutaneously in mice (n = 3 mice, 5 tumors/mouse). Following incubation with 8.6 × 10 µM of cetuximab-IRDye800CW in vitro, serial dilutions of each cell type (1 × 10 -1 × 10 ) were implanted subcutaneously (n = 3, 5 tumors/mouse). Tumors were imaged with Pearl Impulse and Xenogen IVIS 100 imaging systems. Scatchard analysis was performed to determine receptor density and kinetics for each cell line.

Results: Under conditions of minimal cetuximab-IRDye800CW exposure to low cellular quantity, closed-field fluorescence imaging theoretically detected a minimum of 4.2 × 10 -9.5 × 10 2LMP cells, 1.9 × 10 -4.5 × 10 MiaPaca-2 cells, and 2.4 × 10 -6.7 × 10 SCC-1 cells; COLO-205 cells could not be identified. Higher EGFR-mediated uptake of cetuximab correlated with sensitivity of detection.

Conclusion: This study supports the clinical utility of cetuximab-IRDye800CW to sensitively localize subclinical disease in the surgical setting.

Citing Articles

Fluorescently Labeled Cetuximab-IRDye800 for Guided Surgical Excision of Ameloblastoma: A Proof of Principle Study.

Morlandt A, Moore L, Johnson A, Smith C, Stevens T, Warram J J Oral Maxillofac Surg. 2020; 78(10):1736-1747.

PMID: 32554066 PMC: 7541684. DOI: 10.1016/j.joms.2020.05.022.

Tumor-specific near-infrared nanobody probe rapidly labels tumors in an orthotopic mouse model of pancreatic cancer.

Lwin T, Hernot S, Hollandsworth H, Amirfakhri S, Filemoni F, Debie P Surgery. 2020; 168(1):85-91.

PMID: 32370916 PMC: 7311276. DOI: 10.1016/j.surg.2020.02.020.

Nanoparticle Formulation of Indocyanine Green Improves Image-Guided Surgery in a Murine Model of Breast Cancer.

Wojtynek N, Olson M, Bielecki T, An W, Bhat A, Band H Mol Imaging Biol. 2019; 22(4):891-903.

PMID: 31820350 PMC: 7280079. DOI: 10.1007/s11307-019-01462-y.

Characterization of a highly specific NQO1-activated near-infrared fluorescent probe and its application for in vivo tumor imaging.

Punganuru S, Madala H, Arutla V, Zhang R, Srivenugopal K Sci Rep. 2019; 9(1):8577.

PMID: 31189950 PMC: 6562040. DOI: 10.1038/s41598-019-44111-8.

Recommendations for reporting on emerging optical imaging agents to promote clinical approval.

Tummers W, Warram J, van den Berg N, Miller S, Swijnenburg R, Vahrmeijer A Theranostics. 2018; 8(19):5336-5347.

PMID: 30555550 PMC: 6276089. DOI: 10.7150/thno.27384.

References

Niu G, Li Z, Xie J, Le Q, Chen X . PET of EGFR antibody distribution in head and neck squamous cell carcinoma models. J Nucl Med. 2009; 50(7):1116-23. PMC: 6435376. DOI: 10.2967/jnumed.109.061820. View

Warram J, de Boer E, van Dam G, Moore L, Bevans S, Walsh E . Fluorescence imaging to localize head and neck squamous cell carcinoma for enhanced pathological assessment. J Pathol Clin Res. 2016; 2(2):104-12. PMC: 4907060. DOI: 10.1002/cjp2.40. View

Hadjipanayis C, Jiang H, Roberts D, Yang L . Current and future clinical applications for optical imaging of cancer: from intraoperative surgical guidance to cancer screening. Semin Oncol. 2011; 38(1):109-18. PMC: 3061227. DOI: 10.1053/j.seminoncol.2010.11.008. View

Davis N, Sokolosky M, Stadelman K, Abrams S, Libra M, Candido S . Deregulation of the EGFR/PI3K/PTEN/Akt/mTORC1 pathway in breast cancer: possibilities for therapeutic intervention. Oncotarget. 2014; 5(13):4603-50. PMC: 4148087. DOI: 10.18632/oncotarget.2209. View

Thurber G, Weissleder R . Quantitating antibody uptake in vivo: conditional dependence on antigen expression levels. Mol Imaging Biol. 2010; 13(4):623-32. PMC: 3000888. DOI: 10.1007/s11307-010-0397-7. View

Rosenthal E, Warram J, de Boer E, Basilion J, Biel M, Bogyo M . Successful Translation of Fluorescence Navigation During Oncologic Surgery: A Consensus Report. J Nucl Med. 2015; 57(1):144-50. PMC: 4772735. DOI: 10.2967/jnumed.115.158915. View

Marshall M, Draney D, Sevick-Muraca E, Olive D . Single-dose intravenous toxicity study of IRDye 800CW in Sprague-Dawley rats. Mol Imaging Biol. 2010; 12(6):583-94. PMC: 2978892. DOI: 10.1007/s11307-010-0317-x. View

Gioux S, Choi H, Frangioni J . Image-guided surgery using invisible near-infrared light: fundamentals of clinical translation. Mol Imaging. 2010; 9(5):237-55. PMC: 3105445. View

Nicholson R, Gee J, Harper M . EGFR and cancer prognosis. Eur J Cancer. 2001; 37 Suppl 4:S9-15. DOI: 10.1016/s0959-8049(01)00231-3. View

10.

Kalyankrishna S, Grandis J . Epidermal growth factor receptor biology in head and neck cancer. J Clin Oncol. 2006; 24(17):2666-72. DOI: 10.1200/JCO.2005.04.8306. View

11.

Naumov G, Akslen L, Folkman J . Role of angiogenesis in human tumor dormancy: animal models of the angiogenic switch. Cell Cycle. 2006; 5(16):1779-87. DOI: 10.4161/cc.5.16.3018. View

12.

Zinn K, Korb M, Samuel S, Warram J, Dion D, Killingsworth C . IND-directed safety and biodistribution study of intravenously injected cetuximab-IRDye800 in cynomolgus macaques. Mol Imaging Biol. 2014; 17(1):49-57. PMC: 4318248. DOI: 10.1007/s11307-014-0773-9. View

13.

Moore L, Rosenthal E, Chung T, de Boer E, Patel N, Prince A . Characterizing the Utility and Limitations of Repurposing an Open-Field Optical Imaging Device for Fluorescence-Guided Surgery in Head and Neck Cancer Patients. J Nucl Med. 2016; 58(2):246-251. PMC: 5288741. DOI: 10.2967/jnumed.115.171413. View

14.

de Boer E, Warram J, Tucker M, Hartman Y, Moore L, de Jong J . In Vivo Fluorescence Immunohistochemistry: Localization of Fluorescently Labeled Cetuximab in Squamous Cell Carcinomas. Sci Rep. 2015; 5:10169. PMC: 4894408. DOI: 10.1038/srep10169. View

15.

Twaalfhoven F, Peters A, Trimbos J, Hermans J, Fleuren G . The accuracy of frozen section diagnosis of ovarian tumors. Gynecol Oncol. 1991; 41(3):189-92. DOI: 10.1016/0090-8258(91)90306-p. View

16.

Keereweer S, van Driel P, Snoeks T, Kerrebijn J, Baatenburg de Jong R, Vahrmeijer A . Optical image-guided cancer surgery: challenges and limitations. Clin Cancer Res. 2013; 19(14):3745-54. DOI: 10.1158/1078-0432.CCR-12-3598. View

17.

Troiani T, Martinelli E, Capasso A, Morgillo F, Orditura M, De Vita F . Targeting EGFR in pancreatic cancer treatment. Curr Drug Targets. 2012; 13(6):802-10. DOI: 10.2174/138945012800564158. View

18.

Grandis J, Tweardy D . Elevated levels of transforming growth factor alpha and epidermal growth factor receptor messenger RNA are early markers of carcinogenesis in head and neck cancer. Cancer Res. 1993; 53(15):3579-84. View

19.

Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A . Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med. 2004; 351(4):337-45. DOI: 10.1056/NEJMoa033025. View

20.

Kim H, Zhai G, Liu Z, Samuel S, Shah N, Helman E . Extracelluar matrix metalloproteinase as a novel target for pancreatic cancer therapy. Anticancer Drugs. 2011; 22(9):864-74. PMC: 3587034. DOI: 10.1097/CAD.0b013e328349311e. View